Rapid Study Start-up for Phase 1 Dermatology Study in Australia for a UK Biotech Company
PharmaSols was contracted by a small UK-based biotech company to conduct a Phase 1 dermatology clinical trial in Australia. The sponsor was looking to get the study started within a short period of time to achieve the ‘first patient in’ milestone for their investors.
Successful Phase 2 Obesity Clinical Trial in the ANZ Region for a US Biotech Company
PharmaSols was contracted by a small US-based biotech company to conduct a Phase 2 obesity clinical trial. The study required the recruitment of 325 eligible participants across 16 sites in Australia and New Zealand.
PharmaSols achieve rapid start-up for complex 1b oncology study
A US-based biopharmaceutical company was looking to run a Complex 1b Oncology study. The study needed to be handled by a CRO that could manage tight timeframes, and it was imperative that it be carried out without costly interruptions.
Creating Solutions to Deliver Rapid & High-Quality Clinical Trials
Our team have needed to respond quickly to challenges supporting different studies and the experience of our team has enabled us to create rapid solutions for our global sponsors.
Expedited Timeframes and Exceeded Targets for COVID-19 Diagnostic Trial
PharmaSols were engaged by an organisation looking to run a clinical trial for a COVID-19 diagnostic test. It was imperative that this study be carried out without costly interruptions and needed to be handled by a CRO that could manage tight timeframes.
Patient Recruitment Targets Exceeded for COVID-19 Vaccine Trial
Due to PharmaSols unique location and history of successful rapid start-ups, we were engaged by a European specialty vaccine company running a COVID-19 vaccine study. This study needed to be conducted without interruptions caused by the virus itself and with a CRO that could handle tight recruitment timeframes.
Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial
While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.
Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies
Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.
High Recruitment: Twice as many patients as global CRO
Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.
Rapid start-up: First SIV in less than 35 days
Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.
Creative Solutions for US Biotech Clinical Trial
A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.
Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial
After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.
Quick Feasibility for Rare Genetic Trial
A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.
